Methylene Blue has a potent antiviral activity against SARS-CoV-2 and H1N1 influenza virus in the absence of UV-activation in vitro (2021)

Peer-Reviewed Study · Cagno V, Medaglia C, Cerny A, et al. · July 12, 2021

Cagno V et al., 2021-07-12: In-vitro paper recording real virucidal activity of methylene blue against SARS-CoV-2 and H1N1, the document that stands behind the source's virus claims. It is cell-culture work.

Methylene blue is an FDA (Food and Drug Administration) and EMA (European Medicines Agency) approved drug with an excellent safety profile. It displays broad-spectrum virucidal activity in the presence of UV light

Cagno V et al., 2021-07-12: In-vitro paper recording real virucidal activity of methylene blue against SARS-CoV-2 and H1N1, the document that stands behind the source's virus claims. It is cell-culture work. Study type: in vitro. N/A. Country: Switzerland. Low micromolar MB; UV not required for the effect. Funding: not stated. Conflicts: Swiss patent application pending by four authors. Recorded under F1 because the source both asserts and later doubts viral causation: the primary evidence here is in vitro virucidal action, a chemical effect on virions that does not depend on any theory of disease causation. Also filed as MTD-004, MTL-036 (claims C1, C3, F1). Study type: lab.